PBL InterferonSource Introduces VeriKine Cynomolgus/Rhesus Interferon-Alpha Serum ELISA Kit

PBL InterferonSource introduces the new high-sensitivity VeriKine Cynomolgus/Rhesus Interferon-Alpha Serum ELISA kit for determining macaque IFN-Alpha? levels. This assay will enable interferon quantification in Cynomolgus and Rhesus Macaque model systems for viral disease, autoimmune disorders and immunotoxicology. In the past, these models have been used to determine the pathology of deadly human viruses including Ebola, SARS and the 1918 pandemic influenza virus.

VeriKine Cynomolgus/Rhesus IFN-Alpha Serum ELISA kit has superb matrix compatibility. It is sensitive to 25 pg/ml and can detect the protein in a wide variety of sample matrices and test concentrations with an accuracy of +/-20% the expected values in small or large sample sets. The kit performs just as well in Rhesus and Cynomolgus serum and plasma samples.

The kit also detects the bioactive form of the Rhesus/Cynomolgus IFN-Alpha 2 protein suggesting that research can be expedited by minimizing the number of samples to be analyzed in bioassays.

IFN-Alpha can be both protective, as a critical player in host immune responses, and harmful, as a major factor in autoimmune disorders such as Systemic Lupus Erythematosus. The development of this kit to determine the levels of IFN-Alpha in non-human primates should allow for an increased understanding of this duality.

VeriKine Cynomolgus/Rhesus Interferon-Alpha Serum ELISA kit is just one of the high-performance products being developed every day at PBL InterferonSource for the life sciences community. For more information, visit www.interferonsource.com.

About PBL InterferonSource
PBL InterferonSource, a division of Pestka Biomedical Laboratories, Inc. based in Piscataway, NJ, is the world's largest manufacturer and distributor of interferons and related products to the life sciences research market.

SOURCE: PBL InterferonSource